http://www.unboundmedicine.com/medline/ebm/research/alendronateUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19925895/full_citation/Bisphosphonate_Treatment_Modifies_Canine_Bone_Mineral_and_Matrix_Properties_and_their_Heterogeneity_Gourion-Arsiquaud S, Allen MR, Burr DB, et al. 
Bisphosphonate Treatment Modifies Canine Bone Mineral and Matrix Properties and their Heterogeneity. [JOURNAL ARTICLE]
Bone 2009 Nov 16.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19921083/full_citation/Effect_of_alendronate_on_bone_metabolic_indices_and_bone_mineral_density_in_patients_treated_with_high_dose_glucocorticoid:_a_prospective_study_Kaji H, Kuroki Y, Murakawa Y, et al. 
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: a prospective study. [JOURNAL ARTICLE]
Osteoporos Int 2009 Nov 17.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19918047/full_citation/Baseline_Glucocorticoid_Dose_and_Bone_Mineral_Density_Response_with_Teriparatide_or_Alendronate_Therapy_in_Patients_with_Glucocorticoid_induced_Osteoporosis_Devogelaer JP, Adler RA, Recknor C, et al. 
Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Therapy in Patients with Glucocorticoid-induced Osteoporosis. [JOURNAL ARTICLE]
J Rheumatol 2009 Nov 16.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19915945/full_citation/Preferential_reduction_of_bone_mineral_density_at_the_femur_reflects_impairment_of_physical_activity_in_patients_with_low_activity_rheumatoid_arthritis_Sugiguchi S, Goto H, Inaba M, et al. 
Preferential reduction of bone mineral density at the femur reflects impairment of physical activity in patients with low-activity rheumatoid arthritis. [JOURNAL ARTICLE]
Mod Rheumatol 2009 Nov 14.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19898839/full_citation/Prescription_of_anti_osteoporosis_drugs_during_2004_2007_a_nationwide_register_study_in_Norway_Devold HM, Doung GM, Tverdal A, et al. 
Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. [JOURNAL ARTICLE]
Eur J Clin Pharmacol 2009 Nov 7.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19884427/full_citation/Bilateral_low_energy_simultaneous_or_sequential_femoral_fractures_in_patients_on_long_term_alendronate_therapy_Capeci CM, Tejwani NC 
Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. [Journal Article]
J Bone Joint Surg Am 2009 Nov; 91(11):2556-61.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19883401/full_citation/The_Impact_of_Fewer_Hip_Fractures_with_Risedronate_Versus_Alendronate_in_the_First_Year_of_Treatment:_Modeled_German_Cost_Effectiveness_Analysis_Thompson M, Pasquale M, Grima D, et al. 
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness Analysis. [JOURNAL ARTICLE]
Value Health 2009 Oct 26.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19877063/full_citation/Effects_of_teriparatide_versus_alendronate_for_treating_glucocorticoid_induced_osteoporosis:_Thirty_six_month_results_of_a_randomized_double_blind_controlled_trial_Saag KG, Zanchetta JR, Devogelaer JP, et al. 
Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. [Journal Article]
Arthritis Rheum 2009 Nov; 60(11):3346-55.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19859641/full_citation/Use_of_bisphosphonates_and_raloxifene_and_risk_of_deep_venous_thromboembolism_and_pulmonary_embolism_Vestergaard P, Schwartz K, Pinholt EM, et al. 
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism. [JOURNAL ARTICLE]
Osteoporos Int 2009 Oct 27.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19859047/full_citation/Osteoporosis:_recent_physiopatologic_acquisitions_and_new_therapeutic_perspectives_Cesareo R, Napoletano C, Iozzino M, et al. 
Osteoporosis: recent physiopatologic acquisitions and new therapeutic perspectives. [JOURNAL ARTICLE]
Minerva Endocrinol 2009 Sep; 34(3):255-262.
Abstract | Full Citation